Publications by authors named "Brooke Harrow"

Claim this Profile
T
The economic and humanistic burden of tenosynovial giant cell tumor: a targeted literature review.
Michiel van de Sande, Jean-Yves Blay, William Tap, Max Lee, Emily Kaiser, Brooke Harrow

Future Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabozantinib and Axitinib After Vascular Endothelial Growth Factor Therapy in Patients with Advanced Renal Cell Carcinoma: A Retrospective Cohort Study from England.
Janet Brown, Brooke Harrow, Anne Marciniak, Christine McCarthy, Aude Houchard

Drugs Real World Outcomes· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Hans Gelderblom, Vivek Bhadri, Silvia Stacchiotti, Sebastian Bauer, Andrew J Wagner, Brooke Harrow

Lancet· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study.
Hans Gelderblom, Robin L Jones, Jean-Yves Blay, Suzanne George, Margaret von Mehren, Brooke Harrow

Eur J Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting.
Brooke Harrow, Francis Fagnani, Camille Nevoret, Xuan-Mai Truong-Thanh, Marie de Zélicourt

Adv Ther· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting.
Brooke Harrow, Francis Fagnani, Camille Nevoret, Xuan-Mai Truong-Thanh, Marie de Zélicourt

Adv Ther· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting.
Brooke Harrow, Francis Fagnani, Camille Nevoret, Xuan-Mai Truong-Thanh, Marie de Zélicourt

Adv Ther· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world adverse events with niraparib 200 mg/day maintenance therapy in ovarian cancer: a retrospective study.
Jack R Gallagher, Kylee Jean Heap, Susan Carroll, Karin Travers, Brooke Harrow

Future Oncol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budget impact of niraparib as maintenance treatment in recurrent ovarian cancer following platinum-based chemotherapy.
Kurt Neeser, William M O'Neil, Lee Stern, Brooke Harrow, Karin Travers

J Comp Eff Res· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Comparison of Health Care Resource Utilization and Costs for Patients with Allergic Rhinitis on Single-Product or Free-Combination Therapy of Intranasal Steroids and Intranasal Antihistamines.
Brooke Harrow, Ahmad R Sedaghat, Amanda Caldwell-Tarr, Robert Dufour

J Manag Care Spec Pharm· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resource Utilization for Chemotherapy-Induced Nausea and Vomiting Events in Patients with Solid Tumors Treated with Antiemetic Regimens.
Lee Schwartzberg, Brooke Harrow, Lincy S Lal, Janna Radtchenko, Gary H Lyman

Am Health Drug Benefits· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishing the relationship of inhaler satisfaction, treatment adherence, and patient outcomes: a prospective, real-world, cross-sectional survey of US adult asthma patients and physicians.
David Price, Brooke Harrow, Mark Small, James Pike, Victoria Higgins

World Allergy Organ J· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health utilities associated with hemoglobin levels and blood loss in postmenopausal women: the Women's Health Initiative.
Brooke S Harrow, C B Eaton, M B Roberts, A R Assaf, Xuemei Luo

Value Health· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case manager satisfaction in public health.
Russell K Schutt, Jacqueline Fawcett, Gail B Gall, Brooke Harrow, Mary Lou Woodford

Prof Case Manag· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of minimal contact education strategies for cholesterol change.
Kim M Gans, Gary J Burkholder, Patricia M Risica, Brooke Harrow, Thomas M Lasater

Ethn Dis· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of publicly funded managed care on adolescent substance abuse treatment outcomes.
Brooke S Harrow, Christopher P Tompkins, Paul D Mitchell, Kevin W Smith, Stephen Soldz

Am J Drug Alcohol Abuse· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variation in cost of informal caregiving and formal-service use for people with Alzheimer's disease.
Brooke S Harrow, Diane F Mahoney, Aaron B Mendelsohn, Marcia G Ory, David W Coon

Am J Alzheimers Dis Other Demen· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis